Search results
Coya Therapeutics (NASDAQ:COYA) Stock Rating Reaffirmed by Chardan Capital
ETF DAILY NEWS· 5 days agoCoya Therapeutics (NASDAQ:COYA – Get Free Report)‘s stock had its “buy” rating reiterated by Chardan Capital in a note issued to investors on Thursday, Benzinga reports. They ...
Medicare Coverage of Wegovy Raises Questions Regarding the Affordability and Accessibility of Novel...
The National Law Review· 13 hours agoLast week, the Centers for Medicare & Medicaid Services (CMS) announced that it would allow health...
These Expert-Approved High-Frequency Wands Zap Away Acne Without Breaking the Bank
Best Products via Yahoo News· 2 days agoWorden also appreciates that the red light high-frequency wand also comes with a separate body...
Intellia stock price target raised on significant pipeline progress By Investing.com
Investing.com· 5 days agoThe firm increased its price target on the stock to $70.00, up from the previous $62.00, while...
Brokerages Set Immunome, Inc. (NASDAQ:IMNM) PT at $30.50
ETF DAILY NEWS· 1 day agoImmunome, Inc. (NASDAQ:IMNM – Get Free Report) has been given a consensus recommendation of “Buy” by the six research firms that are covering the company, MarketBeat.com reports. Six research ...
Earnings call: Ocugen reports progress in gene therapy trials and Q1 financials By Investing.com
Investing.com· 1 day agoOcugen, Inc. (NASDAQ: NASDAQ:OCGN) discussed significant advancements in its gene therapy programs...
Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com
ETF DAILY NEWS· 6 days agoResearch analysts at StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO – Get Free Report) in a research note issued on Friday. The firm set a “hold” rating ...
Catch up on the day’s stories: Cheap gym memberships, Chevy’s last sedan, psychedelic therapy
CNN via AOL· 6 days agoListen in Psychedelic therapy: CNN’s Audie Cornish talks with an expert about whether these drugs...
Earnings call: MiNK Therapeutics advances in cancer therapy programs By Investing.com
Investing.com· 1 day agoMiNK Therapeutics, a pioneering company in cancer and immune-mediated disease treatment, has...
Vertex Pharmaceuticals (NASDAQ:VRTX) Downgraded by StockNews.com
ETF DAILY NEWS· 5 days agoBarclays lifted their target price on Vertex Pharmaceuticals from $446.00 to $472.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Wolfe ...